Short‑course bortezomib‑based retreatment for patients with multiple myeloma who had received bortezomib‑thalidomide‑dexamethasone (VTD) as an initial therapy: A single‑center case series

Kumar SK, Rajkumar SV, Dispenzieri A, et al: Improved survival in multiple myeloma and the impact of novel therapies. Blood. 111:2516–2520. 2008. View Article : Google Scholar : PubMed/NCBI

Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A and Harousseau JL: Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 120:947–959. 2012.PubMed/NCBI

Hrusovsky I, Emmerich B, von Rohr A, et al: Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland. Oncology. 79:247–254. 2010. View Article : Google Scholar : PubMed/NCBI

Sood R, Carloss H, Kerr R, et al: Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib. Am J Hematol. 84:657–660. 2009. View Article : Google Scholar : PubMed/NCBI

Wolf J, Richardson PG, Schuster M, LeBlanc A, Walters IB and Battleman DS: Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series. Clin Adv Hematol Oncol. 6:755–760. 2008.PubMed/NCBI

Conner TM, Doan QD, Walters IB, LeBlanc AL and Beveridge RA: An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma. Clin Lymphoma Myeloma. 8:140–145. 2008. View Article : Google Scholar : PubMed/NCBI

Shen Y, Zhou X, Wang Z, et al: Coagulation profiles and thromboembolic events of bortezomib plus thalidomide and dexamethasone therapy in newly diagnosed multiple myeloma. Leuk Res. 35:147–151. 2011. View Article : Google Scholar : PubMed/NCBI

Zhou X, Zhu J, Sun H, Shao L, Xu M and Guo H: Family haploidentical donor-derived cytokine-induced killer cell biotherapy combined with bortezomib in two patients with relapsed multiple myeloma in a non-allogeneic transplant setting. Leuk Lymphoma. 54:209–211. 2013. View Article : Google Scholar

Durie BG, Harousseau JL, Miguel JS, et al; International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 20:1467–1473. 2006. View Article : Google Scholar : PubMed/NCBI

National Cancer Institute Cancer Therapy Evaluation Program. Common Toxicity Criteria version 3.0. http://ctep.cancer.gov/forms/ctc2nom-4-30-99-final3.pdfuri. Accessed September 2008

Palumbo A and Anderson K: Multiple myeloma. N Engl J Med. 364:1046–1060. 2011. View Article : Google Scholar

Ma MH, Yang HH, Parker K, et al: The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 9:1136–1144. 2003.PubMed/NCBI

Richardson PG, Mitsiades C, Ghobrial I and Anderson K: Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. Curr Opin Oncol. 18:598–608. 2006. View Article : Google Scholar : PubMed/NCBI

Kapoor P, Ramakrishnan V and Rajkumar SV: Bortezomib combination therapy in multiple myeloma. Semin Hematol. 49:228–242. 2012. View Article : Google Scholar : PubMed/NCBI

Anderson KC, Alsina M, Bensinger W, et al: NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Canc Netw. 7:908–942. 2009.PubMed/NCBI

Mateos MV, Richardson PG, Schlag R, et al: Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 28:2259–2266. 2010. View Article : Google Scholar : PubMed/NCBI

Mohty B, El-Cheikh J, Yakoub-Agha I, Avet-Loiseau H, Moreau P and Mohty M: Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and ‘retreatment’ approaches in the era of novel agents. Leukemia. 26:73–85. 2012.